Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies
Go back to Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies| Merck & Co. (NYSE: MRK) | Delayed: 128.66 +3.21 (2.56%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $125.45 | 52 Week High | $65.46 | |||
| Open | $125.83 | 52 Week Low | $47.97 | |||
| Day High | $128.78 | P/E | 87.52 | |||
| Day Low | $125.83 | EPS | $1.47 | |||
| Volume | 18,891,511 | |||||
